DrugDashboards

Desoximetasone

Desoximetasone · DESOXIMETASONE .5 mg/g · Gel · Topical · Sun Pharmaceutical Industries, Inc.

NDC 51672-1261-01 · 1 TUBE in 1 CARTON / 15 g in 1 TUBE · ANDA · View full market →

The short version

Only one company currently supplies this market — there is no backup if it stumbles. The price has held steady around $3.75 per gram over the past year. Put together: worth watching — several of the pressures that precede supply trouble are present at once.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$3.75per GMinvoice-surveyed acquisition cost · Mar 18, 2026
  • Part D plans paid (avg)$1.11per dosage unitgross, before rebates — matched by drug name · 2024
  • Federal contracts pay (FSS)$52.06per package of 15GMGolden State Medical Supply, Inc. · Oct 15, 2024

Medicare Part D

All Part D pricing →

Matched to CMS's representative package for this drug (NDC 51672-1261-03) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.

ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$4.03per unit
middle half $3.11$4.55 · 650 plans · Apr 1, 2026
Est. net of rebates
≈ $4.03
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
12%of plans cover it
tier 4 · prior auth 0% · step therapy 0% · qty limit 40%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

$0$2.00$4.00$6.00Nov 2013Sep 2026$3.75
33 price points · per GM · held since Invalid DateSource: CMS NADAC

Estimated fill cost

WAC per package, as filed
$73.50
Reported to Texas DSHS · 2026 annual filing · Taro

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicaid spend (2022)

$646
12 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

30Elevated risk

The score is counting real pressure here. One of these alone is routine; it’s the combination that makes this market worth watching.

  • 1 active manufacturer+30

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for desoximetasone (other) in the next 90 days

sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Regulatory

Application
ANDA074904
TE code
AB
Approval date
Jul 14, 1998
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

  • Class II · TerminatedSep 13, 2016
    Taro Pharmaceuticals, Inc.Failed Stability Specifications: The subject lots exhibited OOS results for Homogeneity test (Moderate separation).
  • Class II · TerminatedSep 13, 2016
    Taro Pharmaceuticals, Inc.Failed Stability Specifications: The subject lots exhibited OOS results for Homogeneity test (Moderate separation).

Manufacturers of Desoximetasone (Gel)

LabelerStrengthFirst seenLast seen
Sun Pharmaceutical Industries, Inc.DESOXIMETASONE .5 mg/gJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Desoximetasone — NDC 51672-1261-01," retrieved September 3, 2026, https://drugdashboards.com/drug/51672126101.

Free to cite with attribution — see how the data is put together.